An Open Label, Phase 2 Study to Evaluate Efficacy and Safety of Daratumumab in Relapsed or Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
Phase of Trial: Phase II
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Daratumumab (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma
- Focus Therapeutic Use
- Acronyms CARINA
- Sponsors Janssen Biotech
- 11 Aug 2017 This trial has been completed in Netherlands.
- 07 Jul 2017 This trial has been completed in Belgium.
- 10 Jun 2017 Biomarkers information updated